Labs get clearer rules for a Bacillus anthrax test

For patients and the labs that run these tests, the change is not about paperwork for its own sake. In Washington, the Food and Drug Administration has classified the simple in vitro diagnostic device for detecting secreted proteins from Bacillus species in human clinical samples into class II, and the order takes effect June 22, 2026.

Effective date: June 22, 2026

That puts the test in a middle category. It is not treated as a low-risk device with no added guardrails, but it is also not left in the heavier category that can bring a much more burdensome review.

The new lane for the test

FDA says the device is a prescription in vitro diagnostic used to detect and presumptively identify B. anthracis and other Bacillus species in human clinical samples as an aid in the diagnosis of anthrax and other diseases caused by Bacillus species. The agency says class II is the right fit because the test can be handled safely and effectively when special controls are in place.

Those controls will not sit in a side note. They become part of the codified classification language, which means the rules for the device are built into the federal framework that governs it.

Inside the special controls

The agency says the controls call for careful lab distribution, biosafety safeguards, specific labeling and warnings that a negative result does not rule out infection. Additional confirmation may still be needed before anyone treats the result as final.

That matters because the test can point clinicians in the right direction without pretending to be the whole diagnosis. FDA says the class II finding gives a reasonable assurance of safety and effectiveness, and that it should also reduce regulatory burden and improve access to beneficial innovative devices.

The date on the rule

The order is effective June 22, 2026. FDA also says the classification was applicable on February 3, 2023, which anchors the device’s status in the agency’s records before the final order was published.

For device makers, that kind of defined lane can change how a product moves from design to review. For labs and patients, it can mean a clearer path for a test that still has to clear specific safety checks before it reaches the bedside or bench.